Cite
Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.
MLA
Halbroth, Benedict R., et al. “Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium Falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.” Infection and Immunity, vol. 88, no. 2, Jan. 2020. EBSCOhost, https://doi.org/10.1128/IAI.00573-19.
APA
Halbroth, B. R., Sebastian, S., Salman, A. M., Ulaszewska, M., Gola, A., Longley, R. J., Janse, C. J., Khan, S. M., Hill, A. V. S., & Spencer, A. J. (2020). Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. Infection and Immunity, 88(2). https://doi.org/10.1128/IAI.00573-19
Chicago
Halbroth, Benedict R, Sarah Sebastian, Ahmed M Salman, Marta Ulaszewska, Anita Gola, Rhea J Longley, Chris J Janse, Shahid M Khan, Adrian V S Hill, and Alexandra J Spencer. 2020. “Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium Falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.” Infection and Immunity 88 (2). doi:10.1128/IAI.00573-19.